Drugs / firicabtagene autoleucel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05972720 | Aug 2023 → Apr 2025 | cancer, large B-cell lymphoma | CARGO Therapeutics | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | firicabtagene autoleucel | “This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity...” NCT05972720 ↗ |
| Known as | firi-cel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05972720 ↗ |
| Known as | Firicabtagen autoleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314833 ↗ |
| Target | CD22 | “firi-cel is an autologous CAR T-cell therapy targeting CD22” NCT05972720 ↗ |